N-alpha-Fmoc-Nepsilon-allyloxycarbonyl-D-lysine

CAS : 214750-75-1

Ref. 3D-FF48574

Informations sur le produit

• Nom: N-alpha-Fmoc-Nepsilon-allyloxycarbonyl-D-lysine
• Synonymes: Fmoc-N?-allyloxycarbonyl-D-lysine, (2R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid, <span class="text-smallcaps">D</span>-Lysine, N²-[(9H-fluoren-9-ylmethoxy)carbonyl]-N⁶-[(2-propen-1-yloxy)carbonyl]-, <span class="text-smallcaps">D</span>-Lysine, N²-[(9H-fluoren-9-ylmethoxy)carbonyl]-N⁶-[(2-propenyloxy)carbonyl]-, Fmoc-<span class="text-smallcaps">D</span>-Lys(Alloc), Fmoc-D-Lys(Alloc)-OH, Fmoc-D-Lys(Aloc)-OH, N²-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N⁶-[(2-propen-1-yloxy)carbonyl]-<span class="text-smallcaps">D</span>-lysine
• CAS: 214750-75-1

Description

N-alpha-Fmoc-Nepsilon-allyloxycarbonyl-D-lysine is a medicament that is modified with an amino group at the alpha position. It is synthesized by modification of the chain with a ganirelix acetate. N-alpha-Fmoc-Nepsilon-allyloxycarbonyl-D-lysine can be used to produce ganirelix, which inhibits the release of follicle stimulating hormone (FSH). The chemical synthesis of this drug has been shown to be successful in large scale production, and it has been shown to be effective in treating patients with prostate cancer. Impurities in this drug have been found and treated by removing the methyl ester group from the lysine residue.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 452.5 g/mol
• Formule: C₂₅H₂₈N₂O₆
• Degré de pureté: Min. 95%